<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Drug Details</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <link href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" rel="stylesheet">
    <script>
        tailwind.config = {
            theme: {
                extend: {
                    colors: {
                        primary: '#3b82f6',
                        secondary: '#f3f4f6',
                        accent: '#1e40af',
                        neutral: '#6b7280',
                    },
                    fontFamily: {
                        sans: ['Inter', 'system-ui', 'sans-serif'],
                    },
                }
            }
        }
    </script>
    <style type="text/tailwindcss">
        @layer utilities {
            .content-auto {
                content-visibility: auto;
            }
            .table-hover {
                @apply hover:bg-blue-50 transition-colors duration-200;
            }
            .fade-in {
                animation: fadeIn 0.5s ease-in-out;
            }
            @keyframes fadeIn {
                from { opacity: 0; transform: translateY(10px); }
                to { opacity: 1; transform: translateY(0); }
            }
            .line-item {
                @apply mb-5 p-4 rounded-lg border border-gray-200 bg-white shadow-sm hover:shadow-md transition-shadow;
            }
            .line-label {
                @apply font-semibold text-primary text-lg mb-3;
            }
            .detail-row {
                @apply grid grid-cols-1 md:grid-cols-2 gap-4 py-2 border-b border-gray-100;
            }
            .detail-label {
                @apply font-medium text-gray-700;
            }
            .detail-value {
                @apply text-gray-800;
            }
        }
    </style>
</head>
<body class="bg-gray-50 font-sans text-gray-800 min-h-screen">
    <div class="container mx-auto px-4 py-8 max-w-6xl">
        <!-- Header section -->
        <header class="mb-8 text-center">
            <h1 class="text-[clamp(1.8rem,4vw,2.5rem)] font-bold text-gray-800 mb-2" id="drug-name"></h1>
            <p class="text-gray-600 text-lg">Drug Details</p>
        </header>

        <!-- Back button -->
        <div class="mb-6">
            <a href="yuanshi.html" class="inline-flex items-center px-4 py-2 border border-gray-300 rounded-lg shadow-sm text-sm font-medium text-gray-700 bg-white hover:bg-gray-50 focus:outline-none focus:ring-2 focus:ring-offset-2 focus:ring-primary transition-all duration-200">
                <i class="fa fa-arrow-left mr-2"></i> Back to Search Results
            </a>
        </div>

        <!-- Line-specific details section -->
        <div class="bg-white rounded-xl shadow-lg overflow-hidden transition-all duration-500" id="drug-details-container">
            <!-- Content will be dynamically generated by JavaScript -->
        </div>

        <!-- Footer -->
        <footer class="mt-12 text-center text-gray-500 text-sm">
            <p>Â© 2025 Drug Database | Data for reference only</p>
        </footer>
    </div>

    <script>
        // Get the drug name from the URL
        const urlParams = new URLSearchParams(window.location.search);
        const drugName = urlParams.get('name');

        // Set the drug name in the header
        const drugNameElement = document.getElementById('drug-name');
        drugNameElement.textContent = drugName;

        // Drug-specific detailed information with support for multiple lines and columns
        const drugDetails = {
            "Gefitinib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2005/2/25",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/2/21",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1(8):847-855."
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2011/2/-",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/2/21",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Zhao H, Fan Y, Ma S, et al. Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). J Thorac Oncol. 2015;10(4):655-664."
        }
    }
]
            },
            "Erlotinib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2006/4/-",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/7/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132."
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2015/11/27",
            "Approval Time": "2017/3/10",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/7/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1500109-10",
            "Indication OS follow-up": "Not significant OS benefit",
            "Reference": "Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246."
        }
    },
    {
        name: "1L, maintenance treatment for patients without disease progression after platinum-based therapy",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2010/10/1",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/7/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-529."
        }
    }
]
            },
            "Icotinib hydrochloride": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2011/6/7",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/2/21",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Not significant OS benefit",
            "Reference": "Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14(10):953-961."
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2014/11/13",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2017/2/21",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "2014B02155",
            "Indication OS follow-up": "Not significant OS benefit",
            "Reference": "Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol. 2017;28(10):2443-2450."
        }
    },
    {
        name: "Adjuvant therapy",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2020/9/22",
            "Approval Time": "2021/2/1",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2021/11/24",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2000030",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Afatinib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2016/2/18",
            "Approval Time": "2017/2/21",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1600008-11",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Wu YL, Xu CR, Hu CP, et al. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther. 2018;11:8575-8587."
        }
    },
    {
        name: "2nd or later Lineï¼SCC",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2016/2/18",
            "Approval Time": "2017/2/21",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1600008-11",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Goss GD, Cobo M, Lu S, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021;37:100940."
        }
    }
]
            },
            "Osimertinib": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2017/1/24",
            "Approval Time": "2017/3/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1700005-6",
            "Indication OS follow-up": "Not significant OS benefit",
            "Reference": "Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536-1544."
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2018/10/18",
            "Approval Time": "2019/8/29",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2020/12/25",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1800054-55",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41-50."
        }
    },
    {
        name: "Adjuvant therapy",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2020/9/27",
            "Approval Time": "2021/4/27",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/12/7",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2000150-151",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L, with chemotherapy",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2023/9/21",
            "Approval Time": "2024/6/18",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L, for unresectable stage III NSCLC without disease progression after platinum-based therapy",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2024/6/21",
            "Approval Time": "2024/12/25",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Dacomitinib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2018/5/8",
            "Approval Time": "2019/5/15",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2021/11/24",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1800023-24",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations [published correction appears in J Clin Oncol. 2020 Nov 1;38(31):3725. doi: 10.1200/JCO.20.02783.]. J Clin Oncol. 2018;36(22):2244-2250."
        }
    }
]
            },
            "Almonertinib": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2019/4/15",
            "Approval Time": "2020/3/17",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2020/12/25",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Conversion to regular approval",
            "Review document ID": "CXHS1900011",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/5/19",
            "Approval Time": "2021/12/14",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2101017",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Furmonertinib mesylate": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2019/11/29",
            "Approval Time": "2021/3/2",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2021/11/24",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Conversion to regular approval",
            "Review document ID": "CXHS1900039",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/12/13",
            "Approval Time": "2022/6/28",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2101055",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Befotertinib Mesylate": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/3/1",
            "Approval Time": "2023/5/29",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/12/7",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2100008-09",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/1/19",
            "Approval Time": "2023/9/28",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2300015-16",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Rezivertinib": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/5/7",
            "Approval Time": "2024/5/15",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2024/1/25",
            "Approval Time": "2024/10/29",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Rilertinib Mesylate": {
                lines: [
    {
        name: "2nd or later Line, post-EGFR TKI, EGFR T790M+",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/12/28",
            "Approval Time": "2024/6/11",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/12/15",
            "Approval Time": "2024/9/3",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Zorifertinib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/1/29",
            "Approval Time": "2024/11/15",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Sunvozertinib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/1/10",
            "Approval Time": "2023/8/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2300006-07",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Crizotinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2013/1/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Solomon BJ, Kim DW, Wu YL, et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(22):2251-2258."
        }
    }
]
            },
            "Crizotinib ": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2017/9/25",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Ceritinib": {
                lines: [
    {
        name: "2nd or later Line, post-crizotinib",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2017/11/30",
            "Approval Time": "2018/5/31",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2018/9/30",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1700053",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2019/1/2",
            "Approval Time": "2020/5/27",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2020/12/25",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1900008",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Alectinib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2018/1/11",
            "Approval Time": "2018/8/12",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2020/12/25",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS1800001",
            "Indication OS follow-up": "Significant OS benefit",
            "Reference": "Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056-1064."
        }
    },
    {
        name: "Adjuvant therapy",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2023/11/30",
            "Approval Time": "2024/6/28",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Ensartinib": {
                lines: [
    {
        name: "2nd or later Line, post-crizotinib",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2018/12/25",
            "Approval Time": "2020/11/17",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2021/11/24",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Conversion to regular approval",
            "Review document ID": "CXHS1800045-46",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/7/12",
            "Approval Time": "2022/3/16",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2101028-029",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Brigatinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/1/19",
            "Approval Time": "2022/3/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2100006-008",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Lorlatinib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/4/14",
            "Approval Time": "2022/4/27",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2101002-3",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Iruplinalkib": {
                lines: [
    {
        name: "2nd or later Line, post-crizotinib",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2021/7/21",
            "Approval Time": "2023/6/27",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/12/7",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2101031-032",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/4/3",
            "Approval Time": "2024/1/9",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2300041-42",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Envonalkib": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/11/9",
            "Approval Time": "2024/6/11",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Dabrafenib mesylate plus Trametinib Dimethyl Sulfoxide": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/8/30",
            "Approval Time": "2022/3/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2101043-044",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Fulzerasib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/11/24",
            "Approval Time": "2024/8/20",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Garsorasib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/12/29",
            "Approval Time": "2024/11/5",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Entrectinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/11/11",
            "Approval Time": "2022/8/10",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/12/7",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2101072-73",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Unecritinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2022/6/23",
            "Approval Time": "2024/4/24",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Repotrectinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2023/6/28",
            "Approval Time": "2024/5/8",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Taletrectinib": {
                lines: [
    {
        name: "2nd or later Line, post ROS1 TKI",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2023/11/22",
            "Approval Time": "2024/12/17",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2024/3/4",
            "Approval Time": "2024/12/25",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Pralsetinib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2020/9/8",
            "Approval Time": "2021/3/23",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Conversion to regular approval",
            "Review document ID": "JXHS2000131",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    },
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2022/10/12",
            "Approval Time": "2023/6/21",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2200094",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Selpercatinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2021/11/3",
            "Approval Time": "2022/9/30",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2101070-071",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Savolitinib": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2020/5/28",
            "Approval Time": "2021/6/22",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/1/13",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Conversion to regular approval",
            "Review document ID": "CXHS2000012-13",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Glumetinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2022/2/18",
            "Approval Time": "2023/3/7",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2023/12/7",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2200010",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Vebreltinib": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Only approved by NMPA",
            "New drug application (NDA) acceptance date": "2022/9/23",
            "Approval Time": "2023/11/14",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "CXHS2200047-48",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Tepotinib hydrochloride hydrate": {
                lines: [
    {
        name: "All lines",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2022/3/29",
            "Approval Time": "2023/12/5",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2200033",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Capmatinib Hydrochloride": {
                lines: [
    {
        name: "1L",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2023/2/24",
            "Approval Time": "2024/6/11",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "2024/11/27",
            "Approval pathway": "Regular approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "JXHS2300023-24",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Trastuzumab Deruxtecan": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "2024/2/8",
            "Approval Time": "2024/10/9",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "NA",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            },
            "Mobocertinib succinate": {
                lines: [
    {
        name: "2nd or later Line",
        details: {
            "Market authorization": "Also approved by FDA or EMA",
            "New drug application (NDA) acceptance date": "/",
            "Approval Time": "2023/1/10",
            "First-time inclusion in the National Reimbursement Drug List (NRDL)": "Not included",
            "Approval pathway": "Conditional approval",
            "Regulatory outcomes of conditional approval": "Withdrawal",
            "Review document ID": "/",
            "Indication OS follow-up": "Immature OS benefit",
            "Reference": "/"
        }
    }
]
            }
        };

        // Function to populate the drug details
        function populateDrugDetails() {
            const container = document.getElementById('drug-details-container');
            container.innerHTML = ''; // Clear existing content

            // Check if drug details exist for the selected drug
            if (drugDetails[drugName]) {
                const drug = drugDetails[drugName];

                // Check if the drug uses the new lines structure
                if (drug.lines && drug.lines.length > 0) {
                    // Create a container for all lines
                    const linesContainer = document.createElement('div');
                    linesContainer.className = 'p-4 space-y-5';

                    // Iterate through each line and create a section for it
                    drug.lines.forEach((line, lineIndex) => {
                        const lineSection = document.createElement('div');
                        lineSection.className = `line-item fade-in`;
                        lineSection.style.animationDelay = `${lineIndex * 0.1}s`;

                        // Line name with link to clinical trials page
                        const lineName = document.createElement('div');
                        lineName.className = 'line-label';
                        const link = document.createElement('a');
                        link.href = `clinical_trials.html?drug=${encodeURIComponent(drugName)}&line=${encodeURIComponent(line.name)}`;
                        link.textContent = line.name;
                        lineName.appendChild(link);

                        // Line details table
                        const detailsTable = document.createElement('div');
                        detailsTable.className = 'space-y-1';

                        // Iterate through each detail and create a row
                        for (const [key, value] of Object.entries(line.details)) {
                            const detailRow = document.createElement('div');
                            detailRow.className = 'detail-row';

                            const labelCell = document.createElement('div');
                            labelCell.className = 'detail-label';
                            labelCell.textContent = key;

                            const valueCell = document.createElement('div');
                            valueCell.className = 'detail-value';
                            valueCell.textContent = value;

                            detailRow.appendChild(labelCell);
                            detailRow.appendChild(valueCell);
                            detailsTable.appendChild(detailRow);
                        }

                        // Add line name and details to the line section
                        lineSection.appendChild(lineName);
                        lineSection.appendChild(detailsTable);

                        // Add the line section to the lines container
                        linesContainer.appendChild(lineSection);
                    });

                    // Add the lines container to the main container
                    container.appendChild(linesContainer);
                } else {
                    // Handle the old structure (single line with flat properties)
                    const oldStyleContainer = document.createElement('div');
                    oldStyleContainer.className = 'p-4';

                    // Create a single line item
                    const lineSection = document.createElement('div');
                    lineSection.className = 'line-item fade-in';

                    // Line name (use drugName as fallback if line is not defined)
                    const lineName = document.createElement('div');
                    lineName.className = 'line-label';
                    const link = document.createElement('a');
                    link.href = `clinical_trials.html?drug=${encodeURIComponent(drugName)}&line=${encodeURIComponent(drugName)}`;
                    link.textContent = drug.line || drugName;
                    lineName.appendChild(link);

                    // Line details table
                    const detailsTable = document.createElement('div');
                    detailsTable.className = 'space-y-1';

                    // List of properties to display
                    const properties = [
                        "Market authorization",
                        "New drug application (NDA) acceptance date",
                        "Approval Time",
                        "First-time inclusion in the National Reimbursement Drug List (NRDL)",
                        "Approval pathway",
                        "Regulatory outcomes of conditional approval",
                        "Review document ID",
                        "Indication OS follow-up",
                        "Reference"
                    ];

                    // Iterate through each property and create a row
                    properties.forEach((property) => {
                        const detailRow = document.createElement('div');
                        detailRow.className = 'detail-row';

                        const labelCell = document.createElement('div');
                        labelCell.className = 'detail-label';
                        labelCell.textContent = property;

                        const valueCell = document.createElement('div');
                        valueCell.className = 'detail-value';

                        // Try to find the property in the drug details (handle different casing)
                        const propertyValue = drug[property] ||
                            drug[property.toLowerCase().replace(/ /g, '-')] ||
                            drug[property.replace(/ /g, '')] ||
                            'N/A';

                        valueCell.textContent = propertyValue;

                        detailRow.appendChild(labelCell);
                        detailRow.appendChild(valueCell);
                        detailsTable.appendChild(detailRow);
                    });

                    // Add line name and details to the line section
                    lineSection.appendChild(lineName);
                    lineSection.appendChild(detailsTable);

                    // Add the line section to the container
                    oldStyleContainer.appendChild(lineSection);
                    container.appendChild(oldStyleContainer);
                }
            } else {
                // If no drug details found, show a message
                container.innerHTML = `
                    <div class="p-6 text-center">
                        <i class="fa fa-exclamation-circle text-red-500 text-3xl mb-2"></i>
                        <p class="text-gray-600">Drug details not found for "${drugName}".</p>
                    </div>
                `;
            }
        }

        // Call the function to populate the drug details
        populateDrugDetails();
    </script>
</body>
</html>